Metabolic Side Effects in Patients Using Atypical Antipsychotic Medications During Hospitalization

Dіkeç, Gül; Arabaci, Leyla Baysan; Uzunoğlu, Gülçin; Mızrak, Selin Demet

doi:10.3928/02793695-20180108-05

Cited by 11 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that the occurrence of negative symptoms may be related to antipsychotic drugs [42]. Antipsychotic drug use could result in side effects such as metabolic abnormalities and obesity [17][18][19]. Therefore, this result may be related to antipsychotic drug use.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Wang

Liu

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Schizophrenia patients with a metabolically abnormal obese (MAO) phenotype have been shown poor cardiovascular outcomes, but the characteristics of their current mental symptoms have not been characterized. This study mainly explored the psychiatric symptoms of schizophrenia patients with the MAO phenotype.Methods: A total of 329 patients with schizophrenia and 175 sex- and age-matched people without schizophrenia from Anhui Province in China were enrolled. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the mental symptoms of the schizophrenia patients. The MAO phenotype was defined as meeting 1-4 metabolic syndrome criteria (excluding waist circumference) and having a body mass index (BMI) ≥ 28 kg/m 2 . And, metabolically healthy normal-weight (MHNW) phenotype was defined as meeting 0 criteria for metabolic syndrome and 18.5 ≤ BMI < 24 kg/m 2.Results: Overall, 15.8% of the schizophrenia patients and 9.1% of the control group were consistent with the MAO phenotype, and the prevalence of MAO in the schizophrenia group was higher than that in the control group. Among the patients with schizophrenia, the MAO group had lower negative factor, cognitive factor and total PANSS scores than the MHNW group. However, when confounding factors were controlled, only the negative factor remained lower. The correlation analysis showed that the MAO phenotype was strongly correlated with C-peptide and insulin levels.Conclusion: we found that schizophrenia patients with the MAO phenotype had reduced negative symptoms, which may indicate an internal mechanism linking metabolic disorders and negative symptoms.Trial registration: This study was registered in the China Clinical Trial Registration Center (No. chiCTR 1800017044)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Wang

Liu

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…It is well known that the occurrence of negative symptoms may be related to antipsychotic drugs [48]. Antipsychotic drug use could result in side effects such as metabolic abnormalities and obesity [17][18][19]. Therefore, this result may be related to antipsychotic drug use.…”

Section: Discussionmentioning

confidence: 99%

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Wang

Liu

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Schizophrenia patients with a metabolically abnormal obese (MAO) phenotype have been shown poor cardiovascular outcomes, but the characteristics of their current psychiatric symptoms have not been characterized. This study mainly explored the psychiatric symptoms of schizophrenia patients with the MAO phenotype. Methods: A total of 329 patients with schizophrenia and 175 sex- and age-matched people without schizophrenia from Anhui Province in China were enrolled. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the mental symptoms of the schizophrenia patients. The MAO phenotype was defined as meeting 1-4 metabolic syndrome criteria (excluding waist circumference) and having a body mass index (BMI) ≥ 28 kg/m2. And, metabolically healthy normal-weight (MHNW) phenotype was defined as meeting 0 criteria for metabolic syndrome and 18.5 ≤ BMI < 24 kg/m2. Results: Overall, 15.8% of the schizophrenia patients and 9.1% of the control group were consistent with the MAO phenotype, and the prevalence of MAO in the schizophrenia group was higher than that in the control group. Among the patients with schizophrenia, the MAO group had lower negative factor, cognitive factor and total PANSS scores than the MHNW group. However, when confounding factors were controlled, only the negative factor remained lower. The correlation analysis showed that the MAO phenotype was strongly correlated with C-peptide and insulin levels.Conclusion: we found that schizophrenia patients with the MAO phenotype had reduced negative symptoms, which may indicate an internal mechanism linking metabolic disorders and negative symptoms.Trial registration: This study was registered in the China Clinical Trial Registration Center (No. chiCTR 1800017044)

show abstract

“…Patients with schizophrenia have a high incidence of metabolic side effects and obesity due to the use of second-generation antipsychotics, such as clozapine, olanzapine, and quetiapine [ 17 – 19 ]. Additionally, because of the specific lifestyle characteristics of people with schizophrenia, such as poor diet [ 20 ], sedentary lifestyle [ 21 ] and lack of exercise [ 22 ], the incidence of obesity is increased in this population.…”

Section: Introductionmentioning

confidence: 99%

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

et al. 2020

View full text Add to dashboard Cite

Background: Schizophrenia patients with a metabolically abnormal obese (MAO) phenotype have been shown poor cardiovascular outcomes, but the characteristics of their current psychiatric symptoms have not been characterized. This study mainly explored the psychiatric symptoms of schizophrenia patients with the MAO phenotype. Methods: A total of 329 patients with schizophrenia and 175 sex-and age-matched people without schizophrenia from Anhui Province in China were enrolled. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the mental symptoms of the schizophrenia patients. The MAO phenotype was defined as meeting 1-4 metabolic syndrome criteria (excluding waist circumference) and having a body mass index (BMI) ≥ 28 kg/m 2. And, metabolically healthy normal-weight (MHNW) phenotype was defined as meeting 0 criteria for metabolic syndrome and 18.5 ≤ BMI < 24 kg/m 2. Results: Overall, 15.8% of the schizophrenia patients and 9.1% of the control group were consistent with the MAO phenotype, and the prevalence of MAO in the schizophrenia group was higher than that in the control group. Among the patients with schizophrenia, the MAO group had lower negative factor, cognitive factor and total PANS S scores than the MHNW group. However, when confounding factors were controlled, only the negative factor remained lower significantly. Conclusion: We found that schizophrenia patients with the MAO phenotype had reduced negative symptoms, which may indicate an internal mechanism linking metabolic disorders and negative symptoms. Trial registration: This study was registered in the China Clinical Trial Registration Center (No. chiCTR 1,800,017,044).

show abstract

Metabolic Side Effects in Patients Using Atypical Antipsychotic Medications During Hospitalization

Cited by 11 publications

References 28 publications

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Contact Info

Product

Resources

About